cyrilzakka/clinical-trials huggingface dataset:
Laparoscopic Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) for Colorectal Liver Metastases (CRLM)

Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a procedure used for patients with initially unresectable colorectal liver metastases (CRLM). However, the procedure has been reported to be associated with high morbidity and mortality. Laparoscopic ALPPS has recently been reported as a minimally invasive technique that reduces perioperative risks. This study aimed to assess the safety and feasibility of full laparoscopic ALPPS in patients with CRLM.


Eligibility Criteria:
Inclusion Criteria:

1. Male or female subjects \> 18 years \< 75 of age.
2. ECOG performance status 0-1.
3. Histologically confirmed colorectal adenocarcinoma.
4. Imaging (CT or MRI) or pathological confirmation of liver metastasis.
5. Child-Pugh grade A liver function.
6. FLR/sTLV (standardized total liver volume) \< 30% (patients without underlying liver diseases)or \< 40% (patients with liver diseases, such as hepatic steatosis, cirrhosis, or liver damage after chemotherapy).
7. The indication of surgery is evaluated by a multidisciplinary team attended by hepatobiliary surgeons, oncologists, hepatologists and radiologists.

Exclusion Criteria:

1. Patients with unresectable extrahepatic metastatic disease (except potentially resectable lung metastases) or primary tumor.
2. Patients with severe concomitant diseases who are intolerance of major liver surgery by the judgment of the surgeon.
3. Diagnosis of other malignant tumors within the past 5 years.
4. Intention to become pregnant during the course of the study.
5. Inability to comply with the study protocol.
6. Previous enrollment in the current study.
Topical Rosemary Oil Application in Systemic Sclerosis

The objectives of this prospective crossover, open-label, nonrandomized study are to estimate effect sizes of vasodilatation and sense of warmth after application of topical rosemary essential oil in patients suffering from systemic sclerosis.

In a crossover design, patients suffering from systemic sclerosis (12 subjects) receive applications of olive oil and of 10% Rosmarinus officinalis L. (rosemary) essential oil to both hands with a wash-out period of 3 hours. Effects on vasodilatation are measured with infrared thermography. Patients' sense of warmth is assessed by the "Herdecke warmth perception questionnaire". Measurements take place at baseline and 45 minutes following the interventions (pre-post-comparison). To determine within and between-differences, 2-sample t-tests will be used and effect sizes will be calculated (Standardized Effect Size).

Eligibility Criteria:
Inclusion Criteria:

* Systemic sclerosis with skin involvement of hands and fingers
* Raynaud phenomenon with frequent symptoms of cold hands

Exclusion Criteria:

* Topical treatment with nitroglyceride
* Lymphdrainage \< 24 hours
* Other topical treatment of hands and arms \< 4 hours prior to study intervention
Empirical Comparative Study of Variation Blood Level Antibody Vitamin D at Scleroderma (SSc) Patients Compared Healthy Peoples

The aim is to find the presence of anti vitamin D antibodies in scleroderma patients and compare with control. A second goal is anti vitamin D levels in serum of scleroderma patients in relation to the clinical manifestations of the disease.

Blood samples from 30 scleroderma patients compared to 30 healthy peoples to reach the target of variation of the blood level vitamin D antibody between this groups

Eligibility Criteria:
Inclusion Criteria:

study group

1. patients with SSc
2. age - 18 years old and older
3. sign ICF control group - healthy people
Uterine Artery Doppler Changes

In uncomplicated pregnancies, the uterine spiral arteries undergo a series of structural changes that result in a low resistance in the uterine arteries as pregnancy progresses.

In many pregnancies complicated with preeclampsia, growth restriction and other placental related complication, the described change does not occur. In pregnancies at high risk for placental complications, doppler measurement of Uterine artery flow has been shown to be a reliable predictor of complications.

Postpartum there is a reversal of vascular changes seen in normal pregnancies. It is unclear if there is a full reversal of these changes in complicated pregnancies with abnormal flow during pregnancy.

The investigators hypothesize that Doppler uterine artery measurements after complicated pregnancies will show some abnormality compared to doppler measurements following uncomplicated pregnancies.

The postpartum reversal of pregnancy-related changes in uterine artery (UA) flow is not well documented.

While long-term vascular changes have been noted in women with prior preeclampsia (PE), and in a dose- dependent manner, long-term changes to UA vascular resistance following PE have not been analyzed. Moreover, regardless of whether they experienced PE or intrauterine growth restriction (IUGR), it is not known if women with elevated UA pulsatility index (PI) in mid-pregnancy have higher UA well after pregnancy, compared to women whose UA PI was normal in mid-pregnancy.

The investigators propose to evaluate if UA flow remains abnormally high postpartum in women who had elevated UA flow mid-pregnancy, compared to women whose UA flow was normal in mid-pregnancy.

This is an observational prospective study. The study recruits women that have recently delivered and have undergone a Uterine Doppler ultra sound (US) during the second trimester of their pregnancy. Eligible women will undergo one post-partum ultrasound examination.

Eligibility Criteria:
Inclusion Criteria:

* Women who underwent UA Doppler assessment at 18-22 weeks gestation.
* Viable singleton pregnancy at the time of UA Doppler assessment at 18-22 weeks gestation.
* Is at least 6 weeks postpartum following a livebirth of the aforementioned pregnancy
* Not pregnant at time of post-partum UA Doppler assessment

Exclusion Criteria:

* Women will be excluded if they do not meet the above criteria
Exercise Prescription Dose for Castration Resistance Prostate Cancer Patients

Recent drug improvement (e.g. abiraterone or enzalutamide) for castration resistant prostate cancer (CRPC) patients has improved survival. As treatment strategies improve and patients live longer, patients must cope with their treatment-induced adverse effects. Improving levels of physical activity (PA) and less amounts of sitting time (e.g. sedentary behavior, SB) could have a positive impact on patient's health, non-cancer mortality, and quality of life and potentially improve survival.

The role of PA has not yet been examined in CRPC patients, which is a clear unmet need. No specific PA guidelines exist for CRPC patients, but specific guidelines are warranted because of advanced disease stage, reduced performance score and comorbidity. It is to be expected that the PA level of CRPC patients is lower compared to non-CRPC patients receiving androgen deprivation therapy (ADT).

This study aims to determine the optimal starting physical therapy prescription in CRPC patients receiving second line hormone treatment.

CRPC patients receiving second-line hormone treatment at Ghent University Hospital are invited to participate in this phase I 3+3 dose escalation design (escalation to next exercise dose per 3 study patients). The prescription start dose is 15min. aerobic training (50-80% maximum heart rate (HRmax). warm-up and cooling-down and 65-80%HRmax. core), 1 set with 8-10 reps. resistance training (50-60% one repetition maximum (1RM), 8 exercises) and 1 set (30s.) with 2 reps. flexibility training (5 exercises). Factors determining compliance for the dose are tolerance and safety. Tolerance for the exercise prescription will be assessed with the Borg scale of perceived exertion after every exercise. Compliant for tolerance is a score ≤16. Safety will be assessed by the visual analogue scale (VAS) (assessed by the patient) for pain and the CTCAE criteria (assessed by a trained health care provider) for bone pain after every exercise. Compliant for safety is ≤3 VAS for exercise-induced pain and \<grade 2 according to the CTCAE criteria.

Eligibility Criteria:
Inclusion Criteria:

* CRPC patients with second-line hormone treatment
* Able to walk 400 meters without help from another person
* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule (those conditions should be discussed with the patient before registration in the trial)
* ≥4 weeks since any major surgery and fully recovered before patient registration
* Written informed consent must be given according to International conference on harmonization Good Clinical Practice and national regulation.

Exclusion Criteria:

* Musculoskeletal, cardiovascular or neurological comorbidity that prevent the patient to participate in an exercise program
* Painful bone metastases (VAS) at the time of inclusion
* Unstable bone metastases (SINS classification) at time of inclusion
Effect of Aerobic Exercise Training in Obese Adults

To determine the effect of aerobic exercise training on arterial stiffness and hemodynamics in obese adults. Proper evidence on the effect of aerobic exercise training on both arterial stiffness and hemodynamics are sparsely present in obese adults whereas separate studies were done in mainly hypertensive and cardiovascular disease populations.

Obese adults always have been trying to improve their quality of life by managing the complications associated with obesity like arterial stiffness and disturbed hemodynamics.

Eligibility Criteria:
Inclusion Criteria:

* Body mass index ≥28 kg/m²
* Able to do exercise

Exclusion Criteria:

* Involved in structured physical activity in last 6 months
* History of chronic systemic disease (cardiovascular, pulmonary, and metabolic disease)
* Continuous medication use.
* MSK or Neurological problems
* Pregnant females
Multimodal Machine Learning for Auxiliary Diagnosis of Eye Diseases

With rapid advancements in natural language processing and image processing, there is a growing potential for intelligent diagnosis utilizing chatGPT trained through high-quality ophthalmic consultation. Furthermore, by incorporating patient selfies, eye examination photos, and other image analysis techniques, the diagnostic capabilities can be further enhanced. The multi-center study aims to develop an auxiliary diagnostic program for eye diseases using multimodal machine learning techniques and evaluate its diagnostic efficacy in real-world outpatient clinics.


Eligibility Criteria:
Inclusion Criteria:

* Informed consent obtained;
* Participants should be able to have Chinese as their mother tongue, and be sufficiently able to read, write and understand Chinese;
* For normal participants: individuals should have no concerns related to their eyes.
* For participants with eye-related chief complaints: individuals should have specific concerns or issues related to their eyes.

Exclusion Criteria:

* Incomplete clinical data to support final diagnosis;
* Patients who, in the opinion of the attending physician or clinical study staff, are too medically unstable to participate in the study safely.
Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease

The hypothesis of this trial is to assess the effect of spironolactone on heart size and mass

Dialysis patients have significant morbidity and mortality associated with left ventricular hypertrophy and cardiac failure. Aldosterone may have an important role in the development of myocardial hypertrophy and remodeling. Animal studies have demonstrated beneficial effects of aldosterone antagonists on myocardial hypertrophy, and human studies have shown significant survival benefit in a non-dialysis population with congestive heart failure. This study evaluates the effect of spironolactone (an aldosterone receptor antagonist) on cardiac hypertrophy in the end-stage renal disease population.

Eligibility Criteria:
Inclusion Criteria:

* hemodialysis patients

Exclusion Criteria:

* non compliance
* hyperkalemia
* pregnancy
* expected survival less than 9 months
Markers of Platelet Activation foR Identification of Late Onset Sepsis in Preterm Infants

The PARENT study will examine platelet and endothelial associated proteins in preterm infants being investigated for late onset sepsis (LOS) to see if infants with fulminant sepsis can be prospectively identified using these markers

Infants who are less than 34 weeks corrected gestational age at time of birth will be enrolled prior to any late onset sepsis investigations. At point of clinical concern for the development of late onset sepsis a 0.5-1.3ml sodium citrate sample will be taken. A targeted proteomic analysis using mass spectroscopy and flow cytometry will be performed and compared with the clinical diagnosis of the infant to examine if this can be used prospectively to identify infants with late onset sepsis

Eligibility Criteria:
Inclusion Criteria:

* \<34 weeks corrected gestational age at birth
* Under investigation for Late Onset Neonatal Sepsis (Sepsis of onset \>72 hours of age)

Exclusion Criteria:

* Major congenital anomaly
* Suspicion of an underlying haematological disorder affecting platelets
* Have received a platelet transfusion prior to sampling
Activities of Daily Living in Older Adults

In order to maintain independence and prevent disability, it is essential to identify associated factors and reduce functional loss due to concomitant diseases. This study aimed to examine the effects of frailty, balance, and depression on the performance of activities of daily living in older adults. All participants were assessed using the Mini Mental State Test, simple FRAIL scale, Geriatric Depression Scale-Short Form, and Lawton Instrumental Activities of Daily Living Scale (IADL).

As the global population becomes older, the importance of preserving health, function, and quality of life is being increasingly recognized. In order to maintain independence and prevent disability, it is essential to identify associated factors and reduce functional loss due to concomitant diseases. This study aimed to examine the effects of frailty, balance, and depression on the performance of activities of daily living in older adults. All participants were assessed using the Mini Mental State Test, simple FRAIL scale, Geriatric Depression Scale-Short Form, and Lawton Instrumental Activities of Daily Living Scale (IADL).

Eligibility Criteria:
Inclusion Criteria:

* aged 65 years or older
* being able to understand and answer the questionnaires used for data collection
* having mental competency as demonstrated by a score higher than 20 on the Mini Mental State Test

Exclusion Criteria:

* limited ambulation
* psychological problems
Efficacy of Electroencephalography (EEG) Neurofeedback (NF) for the Treatment of Anxiety Disorder

The aim of this study is to assess the efficacy of electroencephalography (EEG) neurofeedback (NF) as an Add-on Treatment for the Anxiety disorder. Meanwhile, evaluate the effect of EEG-NF on cognitive function of Anxiety patients. Furthermore, the investigators will examine the changes in cortisol, gut microbiome and some biomarkers. The hypothesis of this study is that EEG-NF alleviate the anxiety symptoms and improve the cognitive function of Anxiety disorder patients with regulating attention response.

This is a randomized, double-blind, sham-controlled study using electroencephalography (EEG) neurofeedback (NF) for 2-week treatment. Participants were randomly assigned 1:1 to NF group or sham-control group. The NF group performed six NF sessions every other day in about two weeks. The feedback value of the NF group was about SMR band, while in the control group was pseudo-random numbers. Apart from studying the effects of EEG-NF on severity of anxiety and cognitive function, the secondary outcomes are to examine biomarkers related to inflammatory activity. Scale assessments are performed before the initiation of treatment, week 1, week 2. The Digit Span test, Go/No-Go task Collection of blood, excrement and saliva takes place at two time points, at the baseline, week 2.

Eligibility Criteria:
Inclusion Criteria:

* a current episode of Anxiety diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
* age between 18 and 50 years
* a total score of HAMD ≥14 GAD-7≥ 5
* Participants are compliant with treatment according to the judgement of the treating clinician.
* Participant or guardian has to sign informed consent. The patients' guardians will sign the informed consent on behalf of the participants when the capacity of participants to consent is compromised.

Exclusion Criteria:

* History of alcohol or drug abuse;
* Severe somatic diseases including conditions such as kidney and liver failure, uncontrolled hypertension, cardiovascular, cerebrovascular and pulmonary disease, thyroid disease, diabetes, epilepsy and asthma.
* Use of anti-inflammatory medication for longer than 7 days in the last two months preceding the trial
* Use of immunosuppressive medication such as oral steroid hormones Women in pregnancy or lactation period
Dietary Intake and Nutrient Status of Children With ADHD

Assess the dietary intake of children aged 6-12 years by means of a 24-hour recall and 3-day food record and asses the nutrient status of Vitamin B6, serum ferritin, serum zinc and serum copper of the same children by means of standard laboratory assessments.

* To document the use of vitamin and vitamin-mineral supplements
* To determine the percent consumption of low nutrient density (LND) foods
* To compare the dietary intake of ADHD children with the established standards of the Dietary Reference Intakes (DRIs)
* To compare the dietary intake of children with ADHD to the dietary recommendations of Canada's Food Guide for Healthy Eating
* To determine whether dietary intake is moderated by drug treatment
* To assess the pyridoxal-5'-phosphate (PLP), serum ferritin, serum zinc, and serum copper status of ADHD by standard laboratory blood test
* to measure height and weight in ADHD children

Eligibility Criteria:
Inclusion Criteria:

* Primary diagnosis of ADHD
* Age 6-12 years inclusive

Exclusion Criteria:

* No use of medication that affects dietary intake (eg. Risperdal)
Stability and Outcomes of Non-displaced Lisfranc Injuries

In this multicenter cohort study, the stability of non-displaced Lisfranc injuries as well as their outcomes will be evaluated.

Injuries to the tarsometatarsal joints ("Lisfranc injuries") that are non-displaced on non-weightbearing radiographs and CT are common injuries. To refer these injuries to the right treatment, evaluating their stability is essential. For this purpose, both weightbearing radiographs and stress fluoroscopy have been proposed. However, there is no consensus concerning both the use and interpretation of weightbearing radiographs and no standardized technique and interpretation of stress fluoroscopy in non-displaced Lisfranc injuries.

In the current study, participants will be assigned to non-operative or operative treatment based on Lisfranc joint stability evaluation by weightbearing radiographs.

All Patients with negative weightbearing radiographs will be treated conservatively. In addition, their injured feet will be evaluated by manual stress fluoroscopy. Depending on the result of the stress fluoroscopy (positive/negative), the conservatively treated patients will be assigned to 2 cohorts, whose outcomes will be compared.

Patients with positive weightbearing radiographs will be treated operatively by minimally invasive stabilization of the midfoot (eg. isolated "homerun screw"). The operatively treated patients will be followed up as an independent cohort.

Eligibility Criteria:
Inclusion Criteria:

* Acute Lisfranc injuries that are non-displaced (\< 2mm) on non-weightbearing radiographs and CT
* Patients between 18 and 70 years of age
* Acute presentation at one of our departments, enabling evaluating the stability of the injuries within 4 weeks

Exclusion Criteria:

* Fractures with an intraarticular step of \> 2mm on the initial non weight-bearing radiographs and/or CT
* Delayed presentation (weight-bearing radiographs taken \> 4 weeks after injury)
* Bilateral injuries
* Concomitant major injuries of the foot, ankle or leg that affect the rehabilitation process
* Multitraumized patients
* Previous injury or surgery of the mid foot
* Charcot foot
* Noncompliant patients
* Insufficient Norwegian or English language skills
* Patients not available for follow-up
* Inability to conduct the rehabilitation protocol
Phase 1 BA Study, Single Center With Healthy Volunteers

Single dose in healthy volunteers to assess bioavailability (amount of study drug in the system) between different formulations of ABT-874.


Eligibility Criteria:
Inclusion Criteria:

* Subjects must be healthy

Exclusion Criteria:

* Subjects who are not healthy, enrolled in another study, or who have received ABT-874 previously.